Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Tumor-Agnostic Drug Development.

Offin M, Liu D, Drilon A.

Am Soc Clin Oncol Educ Book. 2018 May 23;(38):184-187. doi: 10.1200/EDBK_200831.

2.

Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion.

Farago AF, Taylor MS, Doebele RC, Zhu VW, Kummar S, Spira AI, Boyle TA, Haura EB, Arcila ME, Benayed R, Aisner DL, Horick NK, Lennerz JK, Le LP, Iafrate AJ, Ou SI, Shaw AT, Mino-Kenudson M, Drilon A.

JCO Precis Oncol. 2018;2. doi: 10.1200/PO.18.00037. Epub 2018 Jul 23.

PMID:
30215037
3.

PD-L1 Expression, Tumor Mutational Burden, and Response to Immunotherapy in Patients with MET exon 14 Altered Lung Cancers.

Sabari JK, Leonardi GC, Shu CA, Umeton R, Montecalvo J, Ni A, Chen R, Dienstag J, Mrad C, Bergagnini I, Lai WV, Offin MD, Arbour KC, Plodkowski AJ, Halpenny DF, Paik PK, Li BT, Riely GJ, Kris MG, Rudin CM, Sholl LM, Nishino M, Hellmann MD, Rekhtman N, Awad MM, Drilon A.

Ann Oncol. 2018 Aug 27. doi: 10.1093/annonc/mdy334. [Epub ahead of print]

PMID:
30165371
4.

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.

Drilon A, Ou SI, Cho BC, Kim DW, Lee J, Lin JJ, Zhu VW, Ahn MJ, Camidge DR, Nguyen J, Zhai D, Deng W, Huang Z, Rogers E, Liu J, Whitten J, Lim JK, Stopatschinskaja S, Hyman DM, Doebele RC, Cui JJ, Shaw AT.

Cancer Discov. 2018 Aug 9. doi: 10.1158/2159-8290.CD-18-0484. [Epub ahead of print]

PMID:
30093503
5.

Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors.

Liu D, Offin M, Harnicar S, Li BT, Drilon A.

Ther Clin Risk Manag. 2018 Jul 20;14:1247-1252. doi: 10.2147/TCRM.S147381. eCollection 2018. Review.

6.

Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers.

Offin M, Rizvi H, Tenet M, Ni A, Sanchez-Vega F, Li BT, Drilon A, Kris MG, Rudin CM, Schultz N, Arcila ME, Ladanyi M, Riely GJ, Yu H, Hellmann MD.

Clin Cancer Res. 2018 Jul 25. pii: clincanres.1102.2018. doi: 10.1158/1078-0432.CCR-18-1102. [Epub ahead of print]

PMID:
30045933
7.

Brief Report: Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients with RET-Rearranged Lung Cancers.

Drilon A, Lin JJ, Filleron T, Ni A, Milia J, Bergagnini I, Hatzoglou V, Velcheti V, Offin M, Li B, Carbone DP, Besse B, Mok T, Awad MM, Wolf J, Owen D, Camidge DR, Riely GJ, Peled N, Kris MG, Mazieres J, Gainor JF, Gautschi O.

J Thorac Oncol. 2018 Jul 11. pii: S1556-0864(18)30780-9. doi: 10.1016/j.jtho.2018.07.004. [Epub ahead of print]

PMID:
30017832
8.

Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.

Li BT, Shen R, Buonocore D, Olah ZT, Ni A, Ginsberg MS, Ulaner GA, Offin M, Feldman D, Hembrough T, Cecchi F, Schwartz S, Pavlakis N, Clarke S, Won HH, Brzostowski EB, Riely GJ, Solit DB, Hyman DM, Drilon A, Rudin CM, Berger MF, Baselga J, Scaltriti M, Arcila ME, Kris MG.

J Clin Oncol. 2018 Aug 20;36(24):2532-2537. doi: 10.1200/JCO.2018.77.9777. Epub 2018 Jul 10.

PMID:
29989854
9.

Selective RET kinase inhibition for patients with RET-altered cancers.

Subbiah V, Velcheti V, Tuch BB, Ebata K, Busaidy NL, Cabanillas ME, Wirth LJ, Stock S, Smith S, Lauriault V, Corsi-Travali S, Henry D, Burkard M, Hamor R, Bouhana K, Winski S, Wallace RD, Hartley D, Rhodes S, Reddy M, Brandhuber BJ, Andrews S, Rothenberg SM, Drilon A.

Ann Oncol. 2018 Aug 1;29(8):1869-1876. doi: 10.1093/annonc/mdy137.

10.

CT features of HER2-mutant lung adenocarcinomas.

Sawan P, Plodkowski AJ, Li AE, Li BT, Drilon A, Capanu M, Ginsberg MS.

Clin Imaging. 2018 Sep - Oct;51:279-283. doi: 10.1016/j.clinimag.2018.05.028. Epub 2018 Jun 7. Review.

11.

Learning All That We Can From MyPathway.

Tao JJ, Schram AM, Harding JJ, Drilon A, Hyman DM.

J Clin Oncol. 2018 Aug 10;36(23):2450-2451. doi: 10.1200/JCO.2018.78.4728. Epub 2018 Jun 1. No abstract available.

PMID:
29856696
12.

Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers.

Drilon A, Somwar R, Mangatt BP, Edgren H, Desmeules P, Ruusulehto A, Smith RS, Delasos L, Vojnic M, Plodkowski AJ, Sabari J, Ng K, Montecalvo J, Chang J, Tai H, Lockwood WW, Martinez V, Riely GJ, Rudin CM, Kris MG, Arcila ME, Matheny C, Benayed R, Rekhtman N, Ladanyi M, Ganji G.

Cancer Discov. 2018 Jun;8(6):686-695. doi: 10.1158/2159-8290.CD-17-1004. Epub 2018 Apr 2.

PMID:
29610121
13.

NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma.

Chiang S, Cotzia P, Hyman DM, Drilon A, Tap WD, Zhang L, Hechtman JF, Frosina D, Jungbluth AA, Murali R, Park KJ, Soslow RA, Oliva E, Iafrate AJ, Benayed R, Ladanyi M, Antonescu CR.

Am J Surg Pathol. 2018 Jun;42(6):791-798. doi: 10.1097/PAS.0000000000001055.

PMID:
29553955
14.

RET fusions in a small subset of advanced colorectal cancers at risk of being neglected.

Pietrantonio F, Di Nicolantonio F, Schrock AB, Lee J, Morano F, Fuca G, Nikolinakos P, Drilon A, Hechtman JF, Christiansen J, Gowen K, Frampton GM, Gasparini P, Rossini D, Gigliotti C, Kim ST, Prisciandaro M, Hodgson J, Zaniboni A, Chiu VK, Milione M, Patel R, Miller V, Bardelli A, Novara L, Wang L, Pupa SM, Sozzi G, Ross J, Di Bartolomeo M, Bertotti A, Ali S, Trusolino L, Falcone A, de Braud F, Cremolini C.

Ann Oncol. 2018 Jun 1;29(6):1394-1401. doi: 10.1093/annonc/mdy090.

PMID:
29538669
15.

Author Correction: Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic target.

Cook PJ, Thomas R, Kannan R, de Leon ES, Drilon A, Rosenblum MK, Scaltriti M, Benezra R, Ventura A.

Nat Commun. 2018 Mar 13;9:16187. doi: 10.1038/ncomms16187.

16.

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.

Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, Nagasubramanian R, Taylor M, Rudzinski ER, Meric-Bernstam F, Sohal DPS, Ma PC, Raez LE, Hechtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS, Hong DS, Hyman DM.

N Engl J Med. 2018 Feb 22;378(8):731-739. doi: 10.1056/NEJMoa1714448.

17.

HER kinase inhibition in patients with HER2- and HER3-mutant cancers.

Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE Jr, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB.

Nature. 2018 Feb 8;554(7691):189-194. doi: 10.1038/nature25475. Epub 2018 Jan 31.

18.

Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.

Drilon A, Hu ZI, Lai GGY, Tan DSW.

Nat Rev Clin Oncol. 2018 Mar;15(3):150. doi: 10.1038/nrclinonc.2017.188. Epub 2017 Nov 28.

PMID:
29182164
19.

Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.

Drilon A, Hu ZI, Lai GGY, Tan DSW.

Nat Rev Clin Oncol. 2018 Mar;15(3):151-167. doi: 10.1038/nrclinonc.2017.175. Epub 2017 Nov 14. Review. Erratum in: Nat Rev Clin Oncol. 2017 Nov 28;:.

PMID:
29134959
20.

RASA1 and NF1 are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Non-Small Cell Lung Carcinomas Sensitive to MEK Inhibition.

Hayashi T, Desmeules P, Smith RS, Drilon A, Somwar R, Ladanyi M.

Clin Cancer Res. 2018 Mar 15;24(6):1436-1447. doi: 10.1158/1078-0432.CCR-17-2343. Epub 2017 Nov 10.

PMID:
29127119
21.

Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance.

Schram AM, Chang MT, Jonsson P, Drilon A.

Nat Rev Clin Oncol. 2017 Dec;14(12):735-748. doi: 10.1038/nrclinonc.2017.127. Epub 2017 Aug 31. Review.

PMID:
28857077
22.

Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.

Hechtman JF, Benayed R, Hyman DM, Drilon A, Zehir A, Frosina D, Arcila ME, Dogan S, Klimstra DS, Ladanyi M, Jungbluth AA.

Am J Surg Pathol. 2017 Nov;41(11):1547-1551. doi: 10.1097/PAS.0000000000000911.

PMID:
28719467
23.

Combination MET- and EGFR-directed therapy in MET-overexpressing non-small cell lung cancers: time to move on to better biomarkers?

Santini FC, Kunte S, Drilon A.

Transl Lung Cancer Res. 2017 Jun;6(3):393-395. doi: 10.21037/tlcr.2017.04.06. No abstract available. Erratum in: Transl Lung Cancer Res. 2017 Oct;6(5):611.

24.

Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic target.

Cook PJ, Thomas R, Kannan R, de Leon ES, Drilon A, Rosenblum MK, Scaltriti M, Benezra R, Ventura A.

Nat Commun. 2017 Jul 11;8:15987. doi: 10.1038/ncomms15987. Erratum in: Nat Commun. 2018 Mar 13;9:16187.

25.

A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.

Drilon A, Nagasubramanian R, Blake JF, Ku N, Tuch BB, Ebata K, Smith S, Lauriault V, Kolakowski GR, Brandhuber BJ, Larsen PD, Bouhana KS, Winski SL, Hamor R, Wu WI, Parker A, Morales TH, Sullivan FX, DeWolf WE, Wollenberg LA, Gordon PR, Douglas-Lindsay DN, Scaltriti M, Benayed R, Raj S, Hanusch B, Schram AM, Jonsson P, Berger MF, Hechtman JF, Taylor BS, Andrews S, Rothenberg SM, Hyman DM.

Cancer Discov. 2017 Sep;7(9):963-972. doi: 10.1158/2159-8290.CD-17-0507. Epub 2017 Jun 3.

26.

Targeting RET-rearranged lung cancers with multikinase inhibitors.

Sabari JK, Siau ED, Drilon A.

Oncoscience. 2017 Apr 14;4(3-4):23-24. doi: 10.18632/oncoscience.345. eCollection 2017 Mar. No abstract available.

27.

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.

Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, Camidge R, Narayanan V, Doebele RC, Besse B, Remon-Masip J, Janne PA, Awad MM, Peled N, Byoung CC, Karp DD, Van Den Heuvel M, Wakelee HA, Neal JW, Mok TSK, Yang JCH, Ou SI, Pall G, Froesch P, Zalcman G, Gandara DR, Riess JW, Velcheti V, Zeidler K, Diebold J, Früh M, Michels S, Monnet I, Popat S, Rosell R, Karachaliou N, Rothschild SI, Shih JY, Warth A, Muley T, Cabillic F, Mazières J, Drilon A.

J Clin Oncol. 2017 May 1;35(13):1403-1410. doi: 10.1200/JCO.2016.70.9352. Epub 2017 Mar 13.

28.

The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers.

Sabari JK, Santini FC, Schram AM, Bergagnini I, Chen R, Mrad C, Lai WV, Arbour KC, Drilon A.

Onco Targets Ther. 2017 Apr 6;10:1983-1992. doi: 10.2147/OTT.S109295. eCollection 2017. Review.

29.

Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.

Jordan EJ, Kim HR, Arcila ME, Barron D, Chakravarty D, Gao J, Chang MT, Ni A, Kundra R, Jonsson P, Jayakumaran G, Gao SP, Johnsen HC, Hanrahan AJ, Zehir A, Rekhtman N, Ginsberg MS, Li BT, Yu HA, Paik PK, Drilon A, Hellmann MD, Reales DN, Benayed R, Rusch VW, Kris MG, Chaft JE, Baselga J, Taylor BS, Schultz N, Rudin CM, Hyman DM, Berger MF, Solit DB, Ladanyi M, Riely GJ.

Cancer Discov. 2017 Jun;7(6):596-609. doi: 10.1158/2159-8290.CD-16-1337. Epub 2017 Mar 23.

30.

Changing the Therapeutic Landscape in Non-small Cell Lung Cancers: the Evolution of Comprehensive Molecular Profiling Improves Access to Therapy.

Sabari JK, Santini F, Bergagnini I, Lai WV, Arbour KC, Drilon A.

Curr Oncol Rep. 2017 Apr;19(4):24. doi: 10.1007/s11912-017-0587-4. Review.

PMID:
28303491
31.

A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.

Smyth LM, Monson KR, Jhaveri K, Drilon A, Li BT, Abida W, Iyer G, Gerecitano JF, Gounder M, Harding JJ, Voss MH, Makker V, Ho AL, Razavi P, Iasonos A, Bialer P, Lacouture ME, Teitcher JB, Erinjeri JP, Katabi N, Fury MG, Hyman DM.

Invest New Drugs. 2017 Dec;35(6):742-750. doi: 10.1007/s10637-017-0445-0. Epub 2017 Mar 9.

PMID:
28281183
32.

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J, Bauer TM, Farago AF, Wheler JJ, Liu SV, Doebele R, Giannetta L, Cerea G, Marrapese G, Schirru M, Amatu A, Bencardino K, Palmeri L, Sartore-Bianchi A, Vanzulli A, Cresta S, Damian S, Duca M, Ardini E, Li G, Christiansen J, Kowalski K, Johnson AD, Patel R, Luo D, Chow-Maneval E, Hornby Z, Multani PS, Shaw AT, De Braud FG.

Cancer Discov. 2017 Apr;7(4):400-409. doi: 10.1158/2159-8290.CD-16-1237. Epub 2017 Feb 9.

33.

Successful Targeted Therapy of Refractory Pediatric ETV6-NTRK3 Fusion-Positive Secretory Breast Carcinoma.

Shukla N, Roberts SS, Baki MO, Mushtaq Q, Goss PE, Park BH, Gundem G, Tian K, Geiger H, Redfield K, Behr G, Benayed R, Zehir A, Hechtman JF, Darnell RB, Papaemmanuil E, Ladanyi M, Ku N, Kung AL, Baselga J, Drilon A, Hyman DM.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00034. Epub 2017 Aug 18. No abstract available.

34.

Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations.

Li GG, Somwar R, Joseph J, Smith RS, Hayashi T, Martin L, Franovic A, Schairer A, Martin E, Riely GJ, Harris J, Yan S, Wei G, Oliver JW, Patel R, Multani P, Ladanyi M, Drilon A.

Clin Cancer Res. 2017 Jun 15;23(12):2981-2990. doi: 10.1158/1078-0432.CCR-16-1887. Epub 2016 Dec 23.

35.

The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials.

Li BT, Barnes TA, Chan DL, Naidoo J, Lee A, Khasraw M, Marx GM, Kris MG, Clarke SJ, Drilon A, Rudin CM, Pavlakis N.

Lung Cancer. 2016 Dec;102:21-27. doi: 10.1016/j.lungcan.2016.10.004. Epub 2016 Oct 17.

36.

Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.

Drilon A, Rekhtman N, Arcila M, Wang L, Ni A, Albano M, Van Voorthuysen M, Somwar R, Smith RS, Montecalvo J, Plodkowski A, Ginsberg MS, Riely GJ, Rudin CM, Ladanyi M, Kris MG.

Lancet Oncol. 2016 Dec;17(12):1653-1660. doi: 10.1016/S1470-2045(16)30562-9. Epub 2016 Nov 4.

37.

Targeted therapy outcomes in RET-rearranged lung cancers: drug or driver?

Drilon A.

Lancet Respir Med. 2017 Jan;5(1):5-6. doi: 10.1016/S2213-2600(16)30369-1. Epub 2016 Nov 4. No abstract available.

PMID:
27825615
38.

Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

Drilon A, Cappuzzo F, Ou SI, Camidge DR.

J Thorac Oncol. 2017 Jan;12(1):15-26. doi: 10.1016/j.jtho.2016.10.014. Epub 2016 Oct 26. Review.

39.

Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.

Drilon A, Bergagnini I, Delasos L, Sabari J, Woo KM, Plodkowski A, Wang L, Hellmann MD, Joubert P, Sima CS, Smith R, Somwar R, Rekhtman N, Ladanyi M, Riely GJ, Kris MG.

Ann Oncol. 2016 Jul;27(7):1286-91. doi: 10.1093/annonc/mdw163. Epub 2016 Apr 7.

40.

MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life.

Drilon A.

Clin Cancer Res. 2016 Jun 15;22(12):2832-4. doi: 10.1158/1078-0432.CCR-16-0229. Epub 2016 Mar 23.

41.

Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets.

Rekhtman N, Pietanza MC, Hellmann MD, Naidoo J, Arora A, Won H, Halpenny DF, Wang H, Tian SK, Litvak AM, Paik PK, Drilon AE, Socci N, Poirier JT, Shen R, Berger MF, Moreira AL, Travis WD, Rudin CM, Ladanyi M.

Clin Cancer Res. 2016 Jul 15;22(14):3618-29. doi: 10.1158/1078-0432.CCR-15-2946. Epub 2016 Mar 9.

42.

Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program.

Drilon A, Eaton AA, Schindler K, Gounder MM, Spriggs DR, Harris P, Ivy SP, Iasonos A, Lacouture ME, Hyman DM.

Cancer. 2016 Apr 15;122(8):1228-37. doi: 10.1002/cncr.29918. Epub 2016 Feb 24.

43.

What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).

Drilon A, Li G, Dogan S, Gounder M, Shen R, Arcila M, Wang L, Hyman DM, Hechtman J, Wei G, Cam NR, Christiansen J, Luo D, Maneval EC, Bauer T, Patel M, Liu SV, Ou SH, Farago A, Shaw A, Shoemaker RF, Lim J, Hornby Z, Multani P, Ladanyi M, Berger M, Katabi N, Ghossein R, Ho AL.

Ann Oncol. 2016 May;27(5):920-6. doi: 10.1093/annonc/mdw042. Epub 2016 Feb 15.

44.

A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer.

Drilon A, Somwar R, Wagner JP, Vellore NA, Eide CA, Zabriskie MS, Arcila ME, Hechtman JF, Wang L, Smith RS, Kris MG, Riely GJ, Druker BJ, O'Hare T, Ladanyi M, Davare MA.

Clin Cancer Res. 2016 May 15;22(10):2351-8. doi: 10.1158/1078-0432.CCR-15-2013. Epub 2015 Dec 16.

45.

KRAS-Mutant Lung Cancers in the Era of Targeted Therapy.

Naidoo J, Drilon A.

Adv Exp Med Biol. 2016;893:155-178. doi: 10.1007/978-3-319-24223-1_8. Review.

PMID:
26667343
46.

Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer.

Dang TO, Ogunniyi A, Barbee MS, Drilon A.

Expert Rev Anticancer Ther. 2016;16(1):13-20. Review.

47.

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.

Farago AF, Le LP, Zheng Z, Muzikansky A, Drilon A, Patel M, Bauer TM, Liu SV, Ou SH, Jackman D, Costa DB, Multani PS, Li GG, Hornby Z, Chow-Maneval E, Luo D, Lim JE, Iafrate AJ, Shaw AT.

J Thorac Oncol. 2015 Dec;10(12):1670-4. doi: 10.1097/01.JTO.0000473485.38553.f0.

48.

A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers.

Li BT, Drilon A, Johnson ML, Hsu M, Sima CS, McGinn C, Sugita H, Kris MG, Azzoli CG.

Ann Oncol. 2016 Jan;27(1):154-9. doi: 10.1093/annonc/mdv498. Epub 2015 Oct 20.

49.

From genotype to phenotype: Are there imaging characteristics associated with lung adenocarcinomas harboring RET and ROS1 rearrangements?

Plodkowski AJ, Drilon A, Halpenny DF, O'Driscoll D, Blair D, Litvak AM, Zheng J, Moskowitz CS, Ginsberg MS.

Lung Cancer. 2015 Nov;90(2):321-5. doi: 10.1016/j.lungcan.2015.09.018. Epub 2015 Sep 21.

50.

Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.

Davare MA, Vellore NA, Wagner JP, Eide CA, Goodman JR, Drilon A, Deininger MW, O'Hare T, Druker BJ.

Proc Natl Acad Sci U S A. 2015 Sep 29;112(39):E5381-90. doi: 10.1073/pnas.1515281112. Epub 2015 Sep 8.

Supplemental Content

Loading ...
Support Center